Stock Events

Stock Events

Sarepta Therapeutics 

$22.50
281
-$0.49-2.13% 20:00 Today
-$0.01-0.04%22:12After hours

Statistics

Day High
22.65
Day Low
21.98
52W High
25.32
52W Low
14.68
Volume
2,869,836
Avg. Volume
3,336,684
Mkt Cap
2.38B
P/E Ratio
54.14
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.6
-2.11
0.39
2.88
Expected EPS
0.172299
Actual EPS
N/A

Financials

-32.45%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.2BRevenue
-713.41MNet Income

Analyst Ratings

22.17Average Price Target
The highest estimate is 37.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
43%
Hold
14%
Sell
43%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRPT. It's not an investment recommendation.
NVIDIA
42
NVDA
Amazon
35
AMZN
AMD
35
AMD
Apple
34
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is developing gene therapies for Duchenne muscular dystrophy (DMD), directly competing with Sarepta's DMD treatments.
Sorrento Therapeutics
SRNE
Mkt Cap385,896
Sorrento Therapeutics has a diverse pipeline including treatments for diseases that Sarepta also targets, making them competitors in the biotech space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical competes with Sarepta in the rare disease space, particularly in treatments for DMD.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics offers treatment for DMD, competing directly with Sarepta's DMD therapies.
Solid Biosciences
SLDB
Mkt Cap1.05B
Solid Biosciences is focused on developing therapies for DMD, positioning it as a direct competitor to Sarepta.
Dyadic International DE
DYAI
Mkt Cap24.6M
Dyadic International is working on developing and manufacturing biopharmaceuticals for diseases that Sarepta also targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other diseases, competing with Sarepta in the broader rare disease market.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical focuses on rare diseases, including some that overlap with Sarepta's target indications.
Biogen
BIIB
Mkt Cap32.28B
Biogen has a broad portfolio in neurology and rare diseases, competing with Sarepta in areas like gene therapy for neurological disorders.

About

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Show more...
CEO
Michael E. Severino
Employees
835
Country
United States
ISIN
US8036071004
WKN
000A1J1BH

Listings

MX
MX
SRPT.MX
MI
IT
1SRPT.MI
SA
BR
S1RP34.SA
LSE
GB
0L35.LSE

0 Comments

Share your thoughts

FAQ

What is Sarepta Therapeutics stock price today?▼
The current price of SRPT is $22.50 USD — it has decreased by -2.13% in the past 24 hours. Watch Sarepta Therapeutics stock price performance more closely on the chart.
What is Sarepta Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Sarepta Therapeutics stocks are traded under the ticker SRPT.
Is Sarepta Therapeutics stock price growing?▼
SRPT stock has risen by +7.86% compared to the previous week, the month change is a +37.28% rise, over the last year Sarepta Therapeutics has showed a +21.89% increase.
What is Sarepta Therapeutics market cap?▼
Today Sarepta Therapeutics has the market capitalization of 2.38B
When is the next Sarepta Therapeutics earnings date?▼
Sarepta Therapeutics is going to release the next earnings report on November 04, 2026.
What were Sarepta Therapeutics earnings last quarter?▼
SRPT earnings for the last quarter are -0.05 USD per share, whereas the estimation was 0.22 USD resulting in a -123.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sarepta Therapeutics revenue for the last year?▼
Sarepta Therapeutics revenue for the last year amounts to 2.2B USD.
What is Sarepta Therapeutics net income for the last year?▼
SRPT net income for the last year is -713.41M USD.
How many employees does Sarepta Therapeutics have?▼
As of September 04, 2026, the company has 835 employees.
In which sector is Sarepta Therapeutics located?▼
Sarepta Therapeutics operates in the Health & Wellness sector.
When did Sarepta Therapeutics complete a stock split?▼
Sarepta Therapeutics has not had any recent stock splits.
Where is Sarepta Therapeutics headquartered?▼
Sarepta Therapeutics is headquartered in CAMBRIDGE, United States.